Aldo N Serafini

Professor

  • 3947 Citations
1972 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Aldo N Serafini is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
Radionuclide Imaging Medicine & Life Sciences
Technetium Medicine & Life Sciences
Radioimmunodetection Medicine & Life Sciences
Blood Platelets Medicine & Life Sciences
Monoclonal Antibodies Medicine & Life Sciences
Bone and Bones Medicine & Life Sciences
Radioisotopes Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1972 2019

  • 3947 Citations
  • 139 Article
  • 1 Chapter
  • 1 Conference contribution
7 Citations (Scopus)

Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Pryma, D. A., Chin, B. B., Noto, R. B., Dillon, J. S., Perkins, S., Solnes, L., Kostakoglu, L., Serafini, A. N., Pampaloni, M. H., Jensen, J., Armor, T., Lin, T., White, T., Stambler, N., Apfel, S., DiPippo, V. A., Mahmood, S., Wong, V. & Jimenez, C., May 1 2019, In : Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 60, 5, p. 623-630 8 p.

Research output: Contribution to journalArticle

Open Access
3-Iodobenzylguanidine
Paraganglioma
Pheochromocytoma
Safety
Therapeutics
6 Citations (Scopus)

Phase II study of <sup>90</sup>Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma

Lossos, I., Fabregas, J. C., Sengul, T., Miao, F., Goodman, D., Serafini, A. N., Hosein, P., Stefanovic, A., Rosenblatt, J. D. & Hoffman, J. E., Jun 1 2015, In : Leukemia and Lymphoma. 56, 6, p. 1750-1755 6 p.

Research output: Contribution to journalArticle

Disease-Free Survival
Lymphoma
Confidence Intervals
Radioimmunotherapy
Survival
59 Citations (Scopus)

Fractionated radioimmunotherapy with 90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial

Ocean, A. J., Pennington, K. L., Guarino, M. J., Sheikh, A., Bekaii-Saab, T., Serafini, A. N., Lee, D., Sung, M. W., Gulec, S. A., Goldsmith, S. J., Manzone, T., Holt, M., O'Neil, B. H., Hall, N., Montero, A. J., Kauh, J., Gold, D. V., Horne, H., Wegener, W. A. & Goldenberg, D. M., Nov 15 2012, In : Cancer. 118, 22, p. 5497-5506 10 p.

Research output: Contribution to journalArticle

gemcitabine
Radioimmunotherapy
Pancreatic Neoplasms
Pancreatic Ductal Carcinoma
Maximum Tolerated Dose
21 Citations (Scopus)

Radiopharmaceuticals: When and how to use them to treat metastatic bone pain

Paes, F. M., Ernani, V., Hosein, P. & Serafini, A. N., Nov 1 2011, In : Journal of Supportive Oncology. 9, 6, p. 197-205 9 p.

Research output: Contribution to journalArticle

Radiopharmaceuticals
Bone and Bones
Pain
Samarium
Neoplasm Metastasis
36 Citations (Scopus)

Utility of positron emission tomography scans in mantle cell lymphoma

Hosein, P., Pastorini, V. H., Paes, F. M., Eber, D., Chapman-Fredricks, J., Serafini, A. N., Alizadeh, A. A. & Lossos, I., Oct 1 2011, In : American Journal of Hematology. 86, 10, p. 841-845 5 p.

Research output: Contribution to journalArticle

Mantle-Cell Lymphoma
Positron-Emission Tomography
Disease-Free Survival
Survival
Confidence Intervals